4.4 Article

Impact of Psychiatric Comorbidity on Health Care Use in Rheumatoid Arthritis: A Population-Based Study

Journal

ARTHRITIS CARE & RESEARCH
Volume 73, Issue 1, Pages 90-99

Publisher

WILEY
DOI: 10.1002/acr.24386

Keywords

-

Categories

Ask authors/readers for more resources

Psychiatric comorbidity in rheumatoid arthritis patients leads to increased healthcare utilization, with more visits, hospitalizations, longer hospital stays, and a higher number of prescribed medications compared to RA patients without psychiatric comorbidity. Managing psychiatric comorbidity effectively may help reduce healthcare utilization in RA.
Objective Psychiatric comorbidity is frequent in rheumatoid arthritis (RA) and complicates treatment. The present study was undertaken to describe the impact of psychiatric comorbidity on health care use (utilization) in RA. Methods We accessed administrative health data (1984-2016) and identified a prevalent cohort with diagnosed RA. Cases of RA (n = 12,984) were matched for age, sex, and region of residence with 5 controls (CNT) per case (n = 64,510). Within each cohort, we identified psychiatric morbidities (depression, anxiety, bipolar disorder, and schizophrenia [PSYC]), with active PSYC defined as >= 2 visits per year. For the years 2006-2016, annual rates of ambulatory care visits (mean +/- SD per person) categorized by provider (family physician [FP], rheumatologist, psychiatrist, other specialist), hospitalization (% of cohort), days of hospitalization (mean +/- SD), and dispensed drug types (mean +/- SD per person) were compared among 4 groups (CNT, CNT plus PSYC, RA, and RA plus PSYC) using generalized linear models adjusted for age, sex, rural versus urban residence, income quintile, and total comorbidities. Estimated rates are reported with 95% confidence intervals (95% CIs). We tested within-person and RA-PSYC interaction effects. Results Subjects with RA were mainly female (72%) and urban residents (59%), with a mean +/- SD age of 54 +/- 16 years. Compared to RA without PSYC, RA with PSYC had more than additive (synergistic) visits (standardized mean difference [SMD] 10.92 [95% CI 10.25, 11.58]), hospitalizations (SMD 13% [95% CI 0.11, 0.14]), and hospital days (SMD 3.63 [95% CI 3.06, 4.19]) and were dispensed 6.85 more medication types (95% CI 6.43, 7.27). Cases of RA plus PSYC had increased visits to FPs (an additional SMD 8.92 [95% CI 8.35, 9.46] visits). PSYC increased utilization in within-person models. Conclusion Managing psychiatric comorbidity effectively may reduce utilization in RA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available